Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Clinical trial NCT00550537 · COMPLETED
Trial details
- NCT number
- NCT00550537
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-10-01
- Primary completion
- 2011-09-01
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.